(Q36445286)

14 August 2017

1 reference

title

Technology insight: monoclonal antibody imaging of prostate cancer (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

Neil H Bander

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

14 August 2017

published in

Nature Reviews Urology

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

216-225

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0452

14 August 2017

exact match

0 references

cites work

The threat of infectious disease in Americans returning from Operation Desert Storm

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Advances in biomedical imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Radioimmunodetection of lymph node invasion in prostatic cancer. The use of iodine 123 (123I)-labeled monoclonal anti-prostatic acid phosphatase (PAP) 227 A F(ab')2 antibody fragments in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Evaluation of preoperative ProstaScint scans in the prediction of nodal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Radioimmunoguided imaging of prostate cancer foci with histopathological correlation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Two different lymph node metastatic patterns of a prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Quantum dots for live cells, in vivo imaging, and diagnostics

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

In vivo cancer targeting and imaging with semiconductor quantum dots

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0452

7 January 2021

Identifiers

DOI

10.1038/NCPURO0452

1 reference

14 August 2017

1 reference